Selected publications
-
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.
European Urology.
2017
Academic Article
GET IT
Times cited: 20 -
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.
European Urology.
2017
Academic Article
GET IT
Times cited: 17 -
Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy.
New England Journal of Medicine.
2016
Academic Article
GET IT
Times cited: 114 -
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
The lancet oncology.
2016
Academic Article
GET IT
Times cited: 188 -
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.
British Journal of Cancer.
2015
Academic Article
GET IT
Times cited: 35 -
Cabozantinib versus everolimus in advanced renal-cell carcinoma.
New England Journal of Medicine.
2015
Academic Article
GET IT
Times cited: 332 -
Nivolumab versus everolimus in advanced renal-cell carcinoma.
New England Journal of Medicine.
2015
Academic Article
GET IT
Times cited: 1246